Breaking News

Mayne Pharma Appoints Blake Cullen VP of Business Development for US Generics

June 16, 2014

Mayne Pharma has apointed Blake Cullen VP of Business Development for its U.S. generic products division.  Mr. Cullen brings over 15 years of industry experience to the position, in the areas of strategic planning, mergers and acquisitions, product in-licensing and out-licensing for companies such as Rhodes Pharma, Libertas Pharma, Paddock Labs and Prasco labs.  With a J.D. degree and an MBA from the University of Cincinnati and a B.S. from Seton Hall, Mr. Cullen has also served as general counsel at Qualitest Pharmaceuticals.  Mayne's generics business, established less than 10 years ago, currently markets more than 20 products and is developing 25 new products, with 13 ANDAs filed with FDA.  Expanding this portfolio will come through both organic development and bolt on acquisitions, said Stefan Cross, Mayne Pharma's president. "Blake brings a strong track record of building pharmaceutical product lines and corporate value," Cross said. 

blog comments powered by Disqus
  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision

  • The Impact of Sample Handling  and Processing on the Outcome of Bioanalytical Testing

    The Impact of Sample Handling and Processing on the Outcome of Bioanalytical Testing

    Haiko Pillu, Head Technical Operations, Life Science Services, SGS Belgium NV||September 8, 2016
    Optimizing bioanalytical procedures to get reliable results in clinical studies

  • Quality Risk Management

    Quality Risk Management

    Cheryl Abernathy and Bryan Sasbon, Quality Assurance Operations Manager, Ropack Pharma Solutions; QA Director & Regulatory Affairs, Ropack Pharma Solutions||September 8, 2016
    Embracing the process as a means to a strong quality culture